MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

ImmunityBio Inc

Închisă

SectorSănătate

3.05 4.1

Rezumat

Modificarea prețului

24h

Curent

Minim

2.89

Maxim

3.12

Indicatori cheie

By Trading Economics

Venit

27M

-59M

Vânzări

1.4M

7.6M

EPS

-0.08

Marjă de profit

-783.62

Angajați

680

EBITDA

946K

-40M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+99.34% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

273M

2.7B

Deschiderea anterioară

-1.05

Închiderea anterioară

3.05

Sentimentul știrilor

By Acuity

21%

79%

47 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

ImmunityBio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 ian. 2025, 15:59 UTC

Principalele dinamici ale pieței

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

23 apr. 2024, 10:51 UTC

Principalele dinamici ale pieței

ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva

24 oct. 2024, 13:50 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Comparație

Modificare preț

ImmunityBio Inc Așteptări

Obiectiv de preț

By TipRanks

99.34% sus

Prognoză pe 12 luni

Medie 6.08 USD  99.34%

Maxim 8 USD

Minim 4.25 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruImmunityBio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.92 / 3.26Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

47 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.